Antidepressant therapy has long been associated with increased risk of suicide in people under 25, but there has been no clear reason why some drugs are more likely than others to have this result and why only a subset of the young adult population is vulnerable. A collaboration of researchers at The University of North Carolina at Chapel Hill and Harvard schools of public health has found that increased suicide risk occurs when young patients are started at a higher dose than is recommended.